Protective effect and mechanism of low P50 haemoglobin oxygen carrier on isolated rat heart
Source abstract
Abstract
The protection of the isolated heart is very important in heart transplantation surgery, meanwhile, the ischaemia/reperfusion (I/R) of the isolated heart is the main cause of its damage. A timely supply of oxygen can significantly improve the prevention of myocardial ischaemia, however, the cardioprotective solution does not have an oxygen supply function. Haemoglobin Based on Oxygen Carriers (HBOCs) is a kind of nano-oxygen drug, which can effectively and timely supply oxygen to hypoxic organs and tissues. However, the oxygen-carrying and releasing capacity (P50) is different with different HBOCs. The aim of our study was to investigate whether STS (a kind of cardioprotective solution, St Thomas Solution) +different P50 HBOCs provide superior myocardial protection and decrease myocardial injury compared to only STS in rats Langendorff isolated heart perfusion model. The results showed that STS + HBOCs can improve cardiac function at 37 °C for 35 min and 120 min, and reduce myocardial infarctions, pathological changes, and apoptosis of cardiomyocytes, and the STS + low P50 HBOCs is more effective than the other two higher P50 HBOCs. We further demonstrated the outstanding protective effect of STS + low P50 HBOCs on cardiac function, reducing myocardial infarctions and apoptosis of cardiomyocytes in rat Langendorff isolated heart perfusion model.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Cardiac Arrest and Resuscitation · Heme Oxygenase-1 and Carbon Monoxide
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China
Department of Anesthesiology and Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, China
References (21)
Show source-provided references
1. 10.1093/icvts/ivu27010.1093/icvts/ivu270 ↗
2. 10.1016/j.atherosclerosis.2013.10.00310.1016/j.atherosclerosis.2013.10.003 ↗
3. 10.3109/21691401.2013.79631110.3109/21691401.2013.796311 ↗
4. 10.1002/wnan.9510.1002/wnan.95 ↗
5. 10.1152/ajpheart.00905.200410.1152/ajpheart.00905.2004 ↗
6. 10.1016/j.freeradbiomed.2008.10.04210.1016/j.freeradbiomed.2008.10.042 ↗
7. 10.1001/jama.299.19.jrv8000710.1001/jama.299.19.jrv80007 ↗
8. 10.1111/j.1537-2995.2009.02356.x10.1111/j.1537-2995.2009.02356.x ↗
9. 10.3109/21691401.2012.74499510.3109/21691401.2012.744995 ↗
10. 10.1007/s00395-017-0605-610.1007/s00395-017-0605-6 ↗
11. 10.1021/acs.bioconjchem.8b0009310.1021/acs.bioconjchem.8b00093 ↗
12. 10.1097/SHK.000000000000104410.1097/SHK.0000000000001044 ↗
13. 10.1016/j.jss.2016.11.04510.1016/j.jss.2016.11.045 ↗
14. 10.1080/21691401.2019.160204910.1080/21691401.2019.1602049 ↗
15. 10.1016/j.freeradbiomed.2019.07.00810.1016/j.freeradbiomed.2019.07.008 ↗
16. 10.1080/21691401.2017.139699910.1080/21691401.2017.1396999 ↗
17. 10.1159/00044865210.1159/000448652 ↗
18. Pan YL, Han ZY, He SF, et al. miR-133b-5p contributes to hypoxic preconditioning-mediated cardioprotection by inhibiting the activation of caspase-8 and caspase-3 in cardiomyocytes. Mol Med Rep. 2018;17(5):7097–7104.
19. 10.3892/ijmm.2017.308910.3892/ijmm.2017.3089 ↗
20. 10.1016/j.toxrep.2019.02.00710.1016/j.toxrep.2019.02.007 ↗
21. 10.1007/s00210-017-1437-510.1007/s00210-017-1437-5 ↗